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ABSTRACT
Among the adipokines, adiponectin is the first one to be described just over a decade ago. It is produced exclusively by adipose tissue and circulates 
in high concentration in human plasma accounting for 0.01% of proteins in plasma, almost thousand times higher than that of leptin. The normal 
circulating level of adiponectin ranges from 2 to 30 µg/ml. It is now observed that besides adipose tissue, adiponectin can also be produced by 
several other tissues such as hepatocytes, cardiomyocytes, and placenta. Adiponectin executes its action via autocrine as well as and paracrine effects. 
Researchers working in this area have revealed that adiponectin has insulin-sensitizing, anti-inflammatory and cardioprotective effects. Our review 
focuses on adiponectin, its mode  of action on different peripheral tissues such as skeletal muscles, heart, liver, brain and its the correlative account 
in various diseases.
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INTRODUCTION
Adiponectin, chief adipokine of adipocytes [1] is a 30 kDa secretory 
protein made up of 244 amino acids [2] coded by APM1 gene located 
on chromosome 3q27 [3]. Not only adipocytes but some other cells 
such as cardiomyocytes, hepatocytes, and placenta also have the 
ability to produce adiponectin in small quantity [2]. It is denoted by 
various terms such as AdipoQ [4], the other ones being gelatin-binding 
protein-28 [5] and adipocyte complement-related protein of 30 kDa [6]. 
Domains present are namely: A C-terminal globular domain, a collagen-
like domain, and an N-terminal domain [3]. Three homooligomeric 
forms of adiponectin namely trimeric form, hexameric form, and 
high molecular weight multimeric form (HMW) have been identified 
in humans [7]. HMW being most active form [8] and the collagenous 
domain being important for the oligomerization [9]. G-protein coupled 
receptors commonly known as adiponectin receptors, viz., adipo R1, 
adipo R2, and T-cadherin modulate the action of adiponectin in various 
tissues. [10]. Major receptor in skeletal muscle is adipo R1, whereas that 
in the liver and vascular endothelial cells is adipo R2 and T-cadherin, 
respectively [11].
ACTION OF ADIPONECTIN ON VARIOUS TISSUES AND ORGANS
As a hormone, adiponectin exhibits autocrine and paracrine action in 
adipose tissue, whereas endocrine activity in distal ones [12].
Adipose tissue
In adipocytes, it regulates cellular differentiation, suppresses 
inflammatory markers such as interleukins (IL6 and 8), inflammatory, 
and chemotactic proteins production, thus inhibiting lipid storage and 
enhancing insulin sensitivity [13].
Skeletal muscles
Earlier, adiponectin was thought to produce its metabolic effects on 
skeletal muscle via endocrine activity [14]. However, according to 
recent studies, myocytes are also capable of secreting adiponectin that 
can exert local effects and hence, it may be regarded as a myokine [15].
Adiponectin has an insulin sensitizing effect on skeletal muscle [9] that 
is achieved by lowering muscular lipid levels [16]. It causes glucose 
utilization [17], uptake of fatty acids and oxidation [18], lowers 
ceramide levels [19] and stimulates mitochondrial biosynthesis [18]. 
These actions are brought about by stimulation of adenosine 
monophosphate kinase (AMPK), peroxisome proliferator activator 
receptor α (PPARα), and p38 mitogen-activated protein kinase [17]. 
AMPK translocates glucose transporter Type 4 transporters to cell 
membrane [20] and regulates glucose utilization and β oxidation, 
whereas PPARα regulates lipid metabolism by controlling the 
expression of genes involved [21]. AMPK renders acetyl-CoA 
carboxylase (ACC) inactive via phosphorylation and decreases levels 
of malonyl-CoA [22], a molecule that allosterically inhibits carnitine 
palmitoyl transferase 1, which is the enzyme required for fatty acid 
transport to mitochondria for oxidation [23]. Fatty acids in muscles are 
derived from triglyceride hydrolysis caused by lipoprotein lipase [24] 
that is activated by adiponectin [25].
Stefan et al. showed a positive association of adiponectin with insulin-
mediated glucose utilization and decreased insulin sensitivity with 
lower adiponectin levels [26]. In a cohort follow-up study, Teros et al. 
stated that older age individuals with hyperinsulinemia possess a 
high risk of skeletal muscle wasting [27]. Ceramide has been recently 
identified as a new factor impairing muscle insulin sensitivity [28]. 
Adiponectin via activation of ceramidase lowers myocellular ceramide 
level and enhances insulin sensitivity as well as mitochondrial 
biosynthesis [19].
Both animal [21] and human studies [29] have confirmed the 
stimulatory role of adiponectin on mitochondrial biosynthesis and its 
oxidative capacity. These effects are mediated via activated AMPK [30]. 
In addition, a strong correlation exists between adiponectin levels and 
mitochondrial DNA content in human skeletal muscle [29].
Cardiovascular system
Adiponectin is considered as cardioprotective adipokine [31] because it 
not only prevents vascular remodeling by suppressing tumor necrosis 
factor α (TNF-α) [32] and platelet-derived growth factor [32] but also 
possesses effective antiatherogenic [33], anti-inflammatory [34], and 
antithrombotic effects [35]. These protective actions are provided via 
the activation of AMPK [36] and cyclooxygenase 2 [37].
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Adiponectin prevents monocyte attachment to endothelium [38] 
and nuclear factor-kappa beta (NF-κβ) signaling, suppressing the 
expression of cell adhesion molecule and IL-8, a proinflammatory 
cytokine [38]. All these effects contribute to the anti-inflammatory role. 
Further, as an antiatherogenic agent, it is able to prevent the formation 
of foam cells. On one hand, it reduces the expression of receptors for 
Class A scavenger [39], whereas, on another hand, it depresses acyl-CoA 
cholesterol acyltransferase enzyme responsible for the synthesis of 
cholesteryl esters [39]. As per Kumada et al., adiponectin upregulates 
IL-10, stabilizes atheromatous plaque [40], and also inhibits thrombus 
formation [41].
Adiponectin as an antioxidant protects the vasculature from oxidative 
stress via augmentation of endothelial nitric oxide synthase (eNOS) 
synthesis [42]. This enzyme is activated by phosphorylation, thereby 
increasing the production of NO [43]. Furthermore, adiponectin also 
suppresses superoxide formation and stimulates eNOS interaction 
with heat shock protein 90 that allows eNOS to render its function at 
maximum level [44].
Adiponectin also regulates fatty acid oxidation and glucose transport 
via mechanism similar to skeletal muscle and thus maintains hydraulic 
work of cardiomyocytes, therefore, increasing cardiac efficiency [45].
Liver
Adiponectin exerts its effect in the liver via activation of AMPK, 
PPARα [12] pathways, and sterol regulatory element-binding protein 1c 
(SREBP) [46]. First, AMPK inactivates ACC by phosphorylation; second, 
it reduces levels of malonyl-CoA, and third, it increases oxidation of fatty 
acids by favoring its transport to mitochondria [47]. In addition, PPARα 
stimulates fatty acid oxidizing enzymes [46] and SREBP 1c, also known 
as a transcription factor, downregulates the lipogenic genes [48].
Adiponectin also exerts antifibrotic through suppression of 
profibrotic factor [49] induced hepatic stellate cells transformation 
to myofibroblast [50]. Adiponectin as an anti-inflammatory agent 
in liver mediates its role by inhibiting TNF-α [51] and activating toll-
like receptor-4 [52]. However, mechanism involved is still unclear and 
requires further researches.
Lungs
Receptors for adiponectin, especially adipo R1 [53], are expressed in 
pulmonary epithelium suggesting lung to be one of the target organs 
of adiponectin [54]. Thyagarajan et al. demonstrated a positive 
relation among lung function and adiponectin [55]. In vitro studies 
on mice model elucidated the protective role of adiponectin against 
inflammation [56] and post-ischemic lung injury [57]. As per Summer 
et al., adiponectin inhibits the action of alveolar macrophages and 
maintains vascular homeostasis [58].
Kidney
Kidney possesses plenty of perirenal fat [59] and expresses adipo 
R1 [60] that on activation by AMPK regulates renal synthetic activities 
and protects glomerulus from oxidative stress. According to Fang et al., 
angiotensin causes activation of nicotinamide adenine dinucleotide 
phosphate (NADH) oxidase and results in oxidative stress, but these 
effects are attenuated by adiponectin [61]. Adiponectin activates 
caspase-8 and preserves podocytes of glomerulus from apoptosis [62]. 
It also upregulates nephrine, a podocyte-derived protein, and decreases 
of which contributes to proteinuria [63]. Adiponectin is mainly cleared 
from the body via liver but kidneys also contribute to some extent [64]. 
Thus, urinary adiponectin, only monomeric and dimeric isoforms, 
can be traced in small quantity [65] as they can cross glomerular 
barrier [66].
Brain
The role of adiponectin in brain and actual mechanism involved is 
poorly elucidated. Although some researches are published in this 
regard, conflicting results are obtained. According to some authors, 
cerebrospinal fluid lacks adiponectin as the brain cells are incapable 
of secreting adiponectin, but they do express its receptors [67]. In 
contrast, recent studies have shown local expression of adiponectin 
in the cells of pituitary gland suggesting that adiponectin may locally 
regulate systemic metabolism through the central nervous system [68]. 
Adiponectin may be also regarded as a starvation gene as there is an 
increase in adiponectin levels in the arcuate hypothalamus during 
fasting state, and this effect may lead to increased hypothalamic AMPK 
activity promoting food intake [69].
ASSOCIATION OF ADIPONECTIN IN VARIOUS PATHOLOGICAL 
CONDITIONS
The serum concentration of circulating adiponectin ranges from 2 to 
30 µg/ml which accounts for 0.01% of proteins present in plasma [70]. 
The level of adiponectin is approximately 40% higher in females as 
compared to males [71]. First, plausible reason for this may be inhibition 
of adiponectin secretion by androgens [9] and second may be gender-
based differential in body fat distribution [72]. Because adiponectin 
affects number of tissues and organs, it has been implicated in various 
pathological states.
Obesity and adiponectin
Obesity, a condition of increased total body fat mass [73], determined by 
anthropometric indices such as body mass index (BMI) [74], waist-hip 
ratio [75] correlate negatively with adiponectin [76] which may be 
due to transcriptional suppression of adiponectin by inflammatory 
cytokines [77], but obese person when reduce their weight [78] 
leads to increase in adiponectin level suggesting reversibility of 
obesity-associated hypoadiponectinemia [79]. Hoffstedt et al. 
reported lower adiponectin mRNA in obese person [80]. Adiponectin 
gene polymorphism at 276 G>T is linked with obesity and related 
complication [81].
Diabetes and adiponectin
Adiponectin is considered to be the potent biomarker of Type 2 
diabetes mellitus [82]. Jee et al. [83] and Tan et al. [84] demonstrated 
the negative relation of adiponectin with diabetes prevalence and 
the risk of prediabetic to develop diabetes. In addition, marker of 
glycemic control, also called glycated hemoglobin, correlated inversely 
with adiponectin [85]. Complications of the diabetes are also shown 
to be associated with adiponectin. It is involved in pathogenesis of 
diabetic retinopathy, one of the major causes of blindness [86]. Lower 
level has been detected in the diabetic patients with retinopathy 
than those without it [86]. Further similar level of adiponectin was 
observed in normoalbuminuric and microalbuminuric patients, 
whereas the concentration was high in diabetic patients having 
macroalbuminuria  [87]. Lin et al. in their study including 733 diabetic 
patients observed that serum adiponectin is inversely correlated 
with the presence of renal dysfunction [88]. In diabetic patients, 
there is increased the risk of cardiovascular complication as the level 
of adiponectin decreases [89]. According to Gligor et al., adiponectin 
protects myocardium by increasing the level of cardioprotective agent 
high-density lipoprotein (HDL) cholesterol [90].
Researches have shown that one of the mechanisms, by which drugs 
used for the treatment of diabetics acts, is by increasing adiponectin 
levels [91] suggesting that adiponectin might be used as a novel 
therapeutic regimen for insulin resistance and Type 2 diabetes.
Adiponectin and cardiovascular diseases
Several studies have supported the roles of low adiponectin in the 
development of vascular disease [92]. Inverse relation of adiponectin 
with carotid intimal thickening [33], myocardial infarction [93], and 
essential hypertension [94] has been observed. Factors that determine 
the cardiovascular disorder risk such as serum cholesterol and 
triglycerides were negatively correlated, whereas HDL was positively 
correlated with adiponectin [29].
As stated in previous studies, adiponectin protects ischemic 
myocardium by suppressing the activity of NADH oxidase and inducible 
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NOS [95]. Adiponectin also correlates positively with progenitor cells 
involved in vascular repair [96]. It modulates angiotensin II action in 
hypertension and renders protective effect [97]. Kumada et al. linked 
hypoadiponectinemia independently with coronary artery disease in 
men [98].
Although cardioprotective in action, increased adiponectin is a risk 
factor of heart failure and cardiovascular mortality [99], especially 
in cachexic patients [100]. The causative factor may be adiponectin 
resistance or increased production of brain natriuretic peptide, a 
vascular disease marker [101]. Some studies, such as those of Lindsay 
et al. [102], Lawlor et al. [103], and Sattar et al. [104], could not obtain 
any association between adiponectin levels and cardiovascular disease 
status. Therefore, the role of adiponectin in coronary artery disease 
development remains controversial, and the possible reason for the 
anomaly may be that the heart disease causes decreased adiponectin 
clearance by affecting kidney function thereby conflicting the analysis.
Adiponectin and inflammation
Increased levels of serum adiponectin have been found in the 
inflammatory disorders such as systemic lupus erythematosus [105], 
cystic fibrosis [106], inflammatory bowel disease [107], and 
rheumatoid arthritis [108]. Anti-inflammatory effects of adiponectin 
are rendered by direct action on inflammatory cells [109], suppression 
of NF-κβ [52], inhibition of TNF-α [110], C-reactive protein (CRP) [111], 
and IL-8 [112] production. Further, it binds with C1q induces classical 
complement system and facilitates apoptotic cell clearance [113]. 
Venkatesh et al. have shown an inverse association between CRP and 
adiponectin levels [114] similar to that of Engeli et al., who also found 
a significant inverse correlation of adiponectin with the inflammatory 
mediators such as CRP and IL-6 [115].
Adiponectin and malignancies
Obesity-related malignancies can develop at different sites of the 
body such as endometrium, breast colon, stomach, and prostate; all 
of which are negatively associated with adiponectin [116]. It may be 
either due to the indirect effects of adiponectin through hormonal and 
cytokine level modifications or due to direct effects through inhibition 
of mitogenic growth factors related to cell proliferation [117]. A meta-
analysis research of Wei et al., on the association of adiponectin with the 
development of cancer, indicated that the circulating adiponectin was 
lower in the patients with various cancers [118]. Study of Kang et al. 
revealed that the breast cancer patients with lower median adiponectin 
are more prone to lymph node metastasis [119].
The risk of endometrial cancer in women having high BMI and low 
adiponectin level increases nearly by 6-folds [120]. Men with the 
highest adiponectin concentration have almost 60% reduced the risk of 
colorectal cancer [121] and nearly 70% reduced the risk of developing 
prostate cancer [122]. Small case-control study has shown a negative 
association of renal carcinoma [123] and acute myeloblastic leukemia 
with adiponectin [116] supporting the fact that adiponectin treatment 
suppresses myelomonocyte cell proliferation [110].
Adiponectin and other disorders
Studies have established role of adiponectin in other peripheral tissues 
such as lungs, liver, and kidney disorders too. A recent study on mice 
with genetic deficiency of adiponectin demonstrated increased systemic 
and local inflammation, alveolar simplification, and enlargement due 
to abnormal postnatal alveolar development [55]. These defects in 
such mice were attenuated by adenoviral adiponectin therapy [124]. 
Decreased serum adiponectin correlated with poor asthmatic lung 
function and chronic obstructive pulmonary disease [125].
In hepatocytes, lower adiponectin level is seen hepatic steatosis [126] 
fatty liver and injuries [127]. Due to insulin resistance, there is 
increased lipolysis in adipocytes but increased lipogenesis in 
hepatocytes causing accumulation of lipid [128]. However, increased 
levels of adiponectin have been detected in liver cirrhosis. Possible 
reasons may be decreased hepatic clearance or compensation to excess 
production of proinflammatory cytokines [34]. Available researches 
indicated adiponectin to be renoprotective [129]. It protects the kidney 
from progression toward fibrosis and hypertrophy [130]. Doumatey 
et al. observed an inverse relationship of adiponectin with estimated 
glomerular filtration rate (GFR) [131], whereas Kawamoto et al. found 
a positive association of HMW adiponectin with GFR [132]. Several 
studies have reported a significant excretion of adiponectin in the urine 
of patients with various renal diseases, whereas the question is still 
unanswered that whether adiponectin is synthesized within nephron 
itself or simply filtered by glomerulus [133].
CONCLUSION
The purpose of this review is not to requote whatever has been 
done in earlier investigations but is to help the researchers who are 
investigating the utility of adiponectin in different sectors of health. 
The pathophysiology of various inflammatory diseases, cancer, and 
disorders related to kidney, lung, liver, and their association with 
adiponectin remain unclear. This review may be worthful for the 
researchers to elucidate such unclear facts and the related mechanism 
behind this. In conclusion, among the various adipokines, adiponectin is 
the abundant protein produced by adipose tissue. It plays an important 
role in carbohydrate and lipid metabolism in various tissues. It has 
been found to be associated with various disorders such as diabetes 
mellitus, atherosclerosis, inflammations, cancers, renal, and pulmonary 
disorders. Further investigations including large sample size are 
required to unveil in depth the clinical roles of adiponectin so that it 
can be used as a potent therapeutic regimen for the management of 
associated disorders in future.
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